Company intelligence / Profile preview

Innoforce Pharmaceuticals

Hangzhou, Zhejiang, Chinalinkedin.com ↗

Ownership: Private
Development stage: Other

Overview

Innoforce has established mature technology platforms enabling end-to-end CDMO services for advanced therapies such as plasmid DNA, mRNA therapeutics, lipid nanoparticles, exosomes, and viral vectors. The company has successfully supported clients through IND-enabling studies to FDA clearance—for example as the CDMO partner for RNAimmune’s RSV mRNA vaccine IND application in the US.

Modalities: Plasmid DNARNAmRNA-based drugsLipid nanoparticle delivery therapyExosome-based therapyViral vectors
Industry: Contract Manufacturing Organization

Partnerships

RNAimmune Inc. (supported RSV mRNA vaccine development)Hibiscus BioVenturesdMed Clinical Research Organization

Beyond the preview

Go deeper on Innoforce Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Innoforce Pharmaceuticals.

Explore the full profile